Radiopharmaceutical therapy (RPT) is emerging as a safe and effective targeted approach
to treating many types of cancer. In RPT, radiation is systemically or locally delivered using …

Astatine-211 (211At) has physical properties that make it one of the top candidates for use
as a radiation source for alpha particle-based radionuclide therapy, also referred to as …

The aim of this evaluation was to identify the first indicators of efficacy for 225Ac-labeled
prostate-specific membrane antigen (PSMA)–617 therapy in a retrospectively analyzed …

The aim of this study was to develop a treatment protocol for 225Ac-PSMA-617 α-radiation
therapy in advanced-stage, metastatic castration-resistant prostate cancer patients with …

Prostate-specific membrane antigen (PSMA)-targeting radio-ligand therapy with beta-
emitting 177 Lutetium has already been investigated in several early phase dosimetry …

Purpose: Prostate-specific membrane antigen (PSMA) is an attractive target for radionuclide
therapy of metastatic castration-resistant prostate cancer (mCRPC). PSMA-targeted alpha …

The aim of this review is to report on the current status of prostate-specific membrane
antigen (PSMA)-directed theranostics in prostate cancer (PC) patients. The value of 68 Ga …

Simple Summary Currently, there is no treatment that can cure patients with late stage
metastatic prostate cancer. Prostate-specific membrane antigen is a type of protein …

Alpha-emitters are radionuclides that decay through the emission of high linear energy
transfer α-particles and possess favorable pharmacologic profiles for cancer treatment …

Prostate cancer is the most commonly diagnosed malignancy in men and the second
leading cause of cancer-related deaths in Western civilization. Although localized prostate …